Mustang Bio to participate in three virtual investor conferences in January 2021


WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs into therapies cell and gene cures in potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, MD, President and CEO, will attend three virtual investor conferences in January 2021.

The details of the events are as follows:

  • tene Annual LifeSci Partners Business Access Event: The company will host one-on-one virtual meetings at the conference from Wednesday January 6 through Friday January 8 and Monday January 11 through Thursday January 14, 2021.

  • HC Wainwright Virtual BioConnect Conference: The company presentation will be available for on-demand viewing on the Mustang website starting Monday, January 11, 2021 at 6:00 a.m. EST.

  • B. Riley Securities Virtual Oncology Investor Conference: The company presentation will take place on Thursday, January 21, 2021 at 1:30 p.m. EST and will be open to all institutional investors registered for the conference.

Webcasts of the presentations by HC Wainwright and B. Riley will be available on the Events page of the Investor Relations section of the Mustang website, www.mustangbio.com, for approximately 30 days after each presentation.

About Mustang Bio
Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and genetic diseases rare. Mustang aims to acquire rights to these technologies by licensing or acquiring an interest, to fund research and development, and to license or commercialize the technologies. Mustang has partnered with leading medical institutions to advance the development of CAR T therapies for several cancers, as well as lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information visit www.mustangbio.com.

Forward-looking statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements include, without limitation, all statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks related to the results of research and development activities; risks associated with the timing of the initiation and completion of clinical trials; uncertainties relating to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our filings with the SEC. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, except as required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company details :
Jaclyn Jaffe and William Begien
Mustang Bio, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Contact person for media relations:
Tony Plohoros
6 degrees
(908) 591-2839
[email protected]

Previous 9 Home buying costs to consider in addition to the down payment
Next 3 financial milestones to be crossed by the age of 30